Delenex Therapeutics AG Report issue

For profit Phase 2
Founded: Zurich Switzerland (2009)
Status: Acquired by Kuur Therapeutics (2016) → now Athenex, Inc. (2021)

Organization Overview

First Clinical Trial
2012
NCT01595997
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

dlx105 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Crohn Disease (Phase 2)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1